StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) Reports Submission of Supplemental Biologics License Application For Prolia (denosumab)
July 31, 2017 9:12 AM
Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Next Articles
Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
July 31, 2017 9:10 AM
Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980
July 31, 2017 9:03 AM
Amgen (AMGN) Declares $1.15 Quarterly Dividend; 2.6% Yield
July 28, 2017 4:01 PM
AbbVie to remain cautious on drug pricing, shares fall
July 28, 2017 7:54 AM
Amgen (AMGN) Says FDA Grants Priority Review For its sBLA For Repatha to Include Data On Reducing Risk Of Cardiovascular Events
July 27, 2017 5:51 PM
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
July 27, 2017 5:50 PM
Amgen (AMGN) PT Raised to $195 at Argus on 2Q Report; 'Contributors to Top-Line Growth: Kyprolis, Prolia & Sensipar'
July 27, 2017 10:11 AM
